Swiss pharmaceutical giant Novartis has said it will cut 2,000 positions, including 1,100 in Switzerland, in the next three to five years.
This content was published on
1 minute
swissinfo.ch and agencies
A further 900 positions will be eliminated in the United States.
The news came as Novartis announced its third quarter results on Tuesday, posting a seven per cent increase in net profit and earnings of $2.49 billion (SFr2.19 billion), up from $2.32 billion for the same period last year.
Sales grew 18 per cent to $14.8 billion in the third quarter, with new products contributing about a quarter, or $3.6 billion. The purchase of Alcon and the relative weakness of the US dollar also added to Novartis’ strong sales, a company statement said.
Along with the 2,000 job losses, the Basel-based company said 700 new positions would be created in low-cost countries, resulting in estimated annual savings of over $200 million.
The Novartis restructuring will overlap with the one under way at fellow Basel-based pharmaceutical giant Roche, which announced 4,800 job cuts worldwide last November.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Drug firms seek cure to profit squeeze
This content was published on
Swiss giants Novartis and Roche reported relatively healthy balance sheets for 2010, but have warned of tough times ahead. The global recession has forced the United States, Japan and European states to demand more for less from drugs firms. Roche estimates that the European and US healthcare measures will cost the group a combined SFr1…
This content was published on
Paul Herrling, the Swiss head of corporate research at pharmaceutical concern Novartis, was among 21 people approved this week to join a WHO expert group evaluating funding for projects into neglected tropical diseases – those illnesses affecting the poorest populations. He is the only expert in the group who is also an executive in the…
This content was published on
The Basel-based multinational aims to save SFr2.4 billion ($2.42 billion) a year by reducing its workforce by 4,800 and outsourcing another 700 positions. Share prices rose on the announcement, but analyst reaction was mixed. The “Operational Excellence Program” unveiled on Wednesday came as no great surprise as Roche had earlier given strong hints that it…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.